S
MLTX icon

SignatureFD’s MoonLake Immunotherapeutics MLTX Stock Holding History

SignatureFD’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$42.3K Buy
2,267
+853
+60% +$14.1K ﹤0.01% 1821
2025
Q4 		$18.6K Buy
1,414
+1,403
+12,755% +$16.6K ﹤0.01% 2154
2025
Q3 		$79 Hold
11
– – ﹤0.01% 3326
2025
Q2 		$519 Buy
+11
New +$448 ﹤0.01% 3102

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SignatureFD's MLTX Position: Q1 2026 in Review

SignatureFD increased its MoonLake Immunotherapeutics (MLTX) stake by 60% in Q1 2026, buying an estimated $14.1K and bringing the position to 2,267 shares worth $42.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1821.

SignatureFD first reported a position in MLTX in Q2 2025 and has held it in 4 quarters since. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • SignatureFD held 2,267 shares of MoonLake Immunotherapeutics worth $42.3K as of Q1 2026.
  • SignatureFD bought 853 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $14.1K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of SignatureFD's portfolio in Q1 2026, its #1821 holding.
  • SignatureFD first reported a position in MoonLake Immunotherapeutics in Q2 2025 and has held it in 4 quarters since.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on SignatureFD's 13F filing for Q1 2026, filed 7 Apr 2026.